CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.
Ulcerative colitis is a gastrointestinal disorder characterized by local inflammation and impaired epithelial barrier. Previous studies demonstrated that CXC chemokine receptor 4 (CXCR4) antagonists could reduce colonic inflammation and mucosal damage in dextran sulfate sodium (DSS)-induced colitis....
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3207859?pdf=render |
id |
doaj-450c38207ffc45f8aa07e1423bc33e2b |
---|---|
record_format |
Article |
spelling |
doaj-450c38207ffc45f8aa07e1423bc33e2b2020-11-25T00:02:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01611e2728210.1371/journal.pone.0027282CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.Xian-Ming XiaFang-Yu WangJu ZhouKai-Feng HuSu-Wen LiBing-Bing ZouUlcerative colitis is a gastrointestinal disorder characterized by local inflammation and impaired epithelial barrier. Previous studies demonstrated that CXC chemokine receptor 4 (CXCR4) antagonists could reduce colonic inflammation and mucosal damage in dextran sulfate sodium (DSS)-induced colitis. Whether CXCR4 antagonist has action on intestinal barrier and the possible mechanism, is largely undefined. In the present study, the experimental colitis was induced by administration of 5% DSS for 7 days, and CXCR4 antagonist AMD3100 was administered intraperitoneally once daily during the study period. For in vitro study, HT-29/B6 colonic cells were treated with cytokines or AMD3100 for 24 h until assay. DSS-induced colitis was characterized by morphologic changes in mice. In AMD3100-treated mice, epithelial destruction, inflammatory infiltration, and submucosal edema were markedly reduced, and the disease activity index was also significantly decreased. Increased intestinal permeability in DSS-induced colitis was also significantly reduced by AMD3100. The expressions of colonic claudin-1, claudin-3, claudin-5, claudin-7 and claudin-8 were markedly decreased after DSS administration, whereas colonic claudin-2 expression was significantly decreased. Treatment with AMD3100 prevented all these changes. However, AMD3100 had no influence on claudin-3, claudin-5, claudin-7 and claudin-8 expression in HT-29/B6 cells. Cytokines as TNF-α, IL-6, and IFN-γ increased apoptosis and monolayer permeability, inhibited the wound-healing and the claudin-3, claudin-7 and claudin-8 expression in HT-29/B6 cells. We suggest that AMD3100 acted on colonic claudin expression and intestinal barrier function, at least partly, in a cytokine-dependent pathway.http://europepmc.org/articles/PMC3207859?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xian-Ming Xia Fang-Yu Wang Ju Zhou Kai-Feng Hu Su-Wen Li Bing-Bing Zou |
spellingShingle |
Xian-Ming Xia Fang-Yu Wang Ju Zhou Kai-Feng Hu Su-Wen Li Bing-Bing Zou CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. PLoS ONE |
author_facet |
Xian-Ming Xia Fang-Yu Wang Ju Zhou Kai-Feng Hu Su-Wen Li Bing-Bing Zou |
author_sort |
Xian-Ming Xia |
title |
CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. |
title_short |
CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. |
title_full |
CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. |
title_fullStr |
CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. |
title_full_unstemmed |
CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. |
title_sort |
cxcr4 antagonist amd3100 modulates claudin expression and intestinal barrier function in experimental colitis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-01-01 |
description |
Ulcerative colitis is a gastrointestinal disorder characterized by local inflammation and impaired epithelial barrier. Previous studies demonstrated that CXC chemokine receptor 4 (CXCR4) antagonists could reduce colonic inflammation and mucosal damage in dextran sulfate sodium (DSS)-induced colitis. Whether CXCR4 antagonist has action on intestinal barrier and the possible mechanism, is largely undefined. In the present study, the experimental colitis was induced by administration of 5% DSS for 7 days, and CXCR4 antagonist AMD3100 was administered intraperitoneally once daily during the study period. For in vitro study, HT-29/B6 colonic cells were treated with cytokines or AMD3100 for 24 h until assay. DSS-induced colitis was characterized by morphologic changes in mice. In AMD3100-treated mice, epithelial destruction, inflammatory infiltration, and submucosal edema were markedly reduced, and the disease activity index was also significantly decreased. Increased intestinal permeability in DSS-induced colitis was also significantly reduced by AMD3100. The expressions of colonic claudin-1, claudin-3, claudin-5, claudin-7 and claudin-8 were markedly decreased after DSS administration, whereas colonic claudin-2 expression was significantly decreased. Treatment with AMD3100 prevented all these changes. However, AMD3100 had no influence on claudin-3, claudin-5, claudin-7 and claudin-8 expression in HT-29/B6 cells. Cytokines as TNF-α, IL-6, and IFN-γ increased apoptosis and monolayer permeability, inhibited the wound-healing and the claudin-3, claudin-7 and claudin-8 expression in HT-29/B6 cells. We suggest that AMD3100 acted on colonic claudin expression and intestinal barrier function, at least partly, in a cytokine-dependent pathway. |
url |
http://europepmc.org/articles/PMC3207859?pdf=render |
work_keys_str_mv |
AT xianmingxia cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis AT fangyuwang cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis AT juzhou cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis AT kaifenghu cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis AT suwenli cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis AT bingbingzou cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis |
_version_ |
1725439097108955136 |